Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Market Closed 12-12 16:00:00 EST

1.41

-0.11

-7.24%

盘后1.43

+0.02+1.42%

19:54 EST

High1.54	Low1.41	Vol1.21M
Open1.53	D1 Closing1.52	Amplitude8.55%
Mkt Cap99.69M	Tradable Cap80.70M	Total Shares70.70M
T/O1.77M	T/O Rate2.11%	Tradable Shares57.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":1.41,"timestamp":1765573200000,"preClose":1.52,"halted":0,"volume":1205466,"hourTrading":{"tag":"盘后","latestPrice":1.43,"preClose":1.41,"latestTime":"19:54 EST","volume":18286,"amount":25830.0164,"timestamp":1765587271898},"delay":0,"floatShares":57237400,"shares":70703639,"eps":-2.204976,"marketStatus":"Market Closed","change":-0.11,"latestTime":"12-12 16:00:00 EST","open":1.53,"high":1.54,"low":1.41,"amount":1774373.8651331998,"amplitude":0.085526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204976,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.52,"preClose":1.52,"latestTime":"09:26 EST","volume":13341,"amount":20133.2179476,"timestamp":1765549607117},"postHourTrading":{"tag":"盘后","latestPrice":1.43,"preClose":1.41,"latestTime":"19:54 EST","volume":18286,"amount":25830.0164,"timestamp":1765587271898},"volumeRatio":0.43900946767471427,"impliedVol":1.1987,"impliedVolPercentile":0.788},"requestUrl":"/m/hq/s/BMEA/tweets","defaultTab":"tweets","newsList":[{"id":"2590320924","title":"Biomea Fusion Highlights Icovamenib Data at WCIRDC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590320924","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590320924?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:35","pubTimestamp":1765323330,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. participated in the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease , where Dr. Ralph DeFronzo, a leading expert in diabetes, delivered a presentation on the future of menin inhibitors and discussed the company's investigational therapy, icovamenib. The event featured a scientific session and an online interview highlighting the clinical results and potential of icovamenib as a disease-modifying therapy for diabetes, including its effects when combined with GLP-1 based therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4Bc42n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","BK4539","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","BMEA","IE00BKPKM429.USD","SG9999014039.USD","NDAQ","BK4112"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","LU0128525929.USD","PKG","AES","TTAN","LU0320765646.SGD","ROL","CDE","FCX","ITT","PSN","EQT","BMEA","TRMB","VSCO","DELL","PRAX","FANG","TE","COO","HPE","DBRG","LU0128525689.USD","HUM","XOM","HL","TARA","LU1150488218.USD","LUV","WBD","FSLY","EXE","ULTA","AUB","ALB","CHPT","S","IOT","EUDA","AMLX","SCCO","RBRK","OMC","ZUMZ"],"gpt_icon":1},{"id":"2589180868","title":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret","url":"https://stock-news.laohu8.com/highlight/detail?id=2589180868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589180868?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:22","pubTimestamp":1764944543,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's SecretEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","ZUMZ","LU0821914370.USD","SW","VSCO","S","TARA","LU1232071149.USD","TRMB","HPE","BK4170","ULTA","SGXZ23171101.USD","WBD","IOT","PKG","LU2039709279.SGD","TTAN","LU1035775433.USD","SWR.UK","LU1863844665.USD","PSN","COO","LU1280957306.USD","LU0719512351.SGD","QCLS","BK4123","RBRK","LU2401740654.USD","89888","ROL","BK4614","LU2477742899.HKD","LUV","CHPT","LU0368265764.SGD","RGEN","IE00B0JY6N72.USD","LU0300736062.USD","INTS","LU1048596156.SGD","LU1989764664.SGD","LU0942090050.USD"],"gpt_icon":1},{"id":"2589894293","title":"BUZZ-Biomea Fusion rises as diabetes drug shows promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894293","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894293?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:18","pubTimestamp":1764937132,"startTime":"0","endTime":"0","summary":"BUZZ-Biomea Fusion rises as diabetes drug shows promise** Shares of drug developer Biomea Fusion BMEA.O rise 3.4% to $1.23 premarket** Co says experimental drug, icovamenib, helped patients with severe type 2 diabetes maintain better blood sugar control nine months after treatment** Study presented at World Congress on Insulin Resistance in Los Angeles, co says** BMEA says drug aims to restore insulin-producing cells; tested in adults who failed up to three standard therapies** No serious side effects reported; further trials planned with GLP-1 users later this year, says co** As of last close, stock down ~69% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BMEA","BK4585","BK4139"],"gpt_icon":0},{"id":"2589894656","title":"Biomea Fusion Reports Durable Glycemic Improvements with Icovamenib in Type 2 Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894656","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894656?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:00","pubTimestamp":1764936016,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. announced the presentation of results from its COVALENT-111 clinical study at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease , held December 3-6, 2025, in Los Angeles. The study evaluated icovamenib, a selective menin inhibitor, in adults with severe insulin-deficient type 2 diabetes. According to the company, icovamenib demonstrated durable glycemic and C-peptide improvements up to 9 months after the last dose, with higher HbA1c reduction associated with greater drug exposure. The treatment was reported to be generally well-tolerated, with no adverse-event related discontinuations or serious adverse events. The full abstract will be published in Metabolism: Experimental and Clinical, and the presentation will be available on Biomea Fusion's Investor Relations page.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8TmX0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","NDAQ","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4112","BK4585","BK4139","BMEA","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2589894588","title":"Biomea Fusion Presents Covalent-111 Study Results at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589894588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589894588?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:00","pubTimestamp":1764936001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA1C6G1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4539","BK4585","BK4139"],"gpt_icon":0},{"id":"2589837434","title":"Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589837434","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589837434?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:15","pubTimestamp":1764882948,"startTime":"0","endTime":"0","summary":"Michael J.M. Hitchcock, Interim CEO and Director of Biomea Fusion Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9KzrP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Interim CEO Michael J.M. Hitchcock Reports Acquisition of Biomea Fusion Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BMEA","BK4139"],"gpt_icon":0},{"id":"2588306620","title":"Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588306620","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588306620?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:15","pubTimestamp":1764710136,"startTime":"0","endTime":"0","summary":"Rainer M. Erdtmann, Director and Officer at Biomea Fusion Inc., reported an acquisition of common shares of Biomea Fusion Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3q1qbG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Biomea Fusion Inc. CEO and Director Rainer M. Erdtmann Reports Acquisition of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BMEA","BK4139"],"gpt_icon":0},{"id":"2588703866","title":"Biomea Fusion Unveils Positive Long-Term Icovamenib Data in Type 2 Diabetes at WCIRDC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703866","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703866?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:10","pubTimestamp":1764623411,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. announced that it will present long-term follow-up data on icovamenib, a menin inhibitor targeting β-cell restoration in insulin-deficient type 2 diabetes, at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease  in Los Angeles, California. The oral presentation, scheduled for December 5, 2025, will feature results from the COVALENT-111 study, highlighting Week 52 data on glycemic and C-peptide improvements in patients. The presentation is one of six selected for oral delivery at the congress, with posters and presentations to be made available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1nYCjr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4539","LU2210149790.SGD","NDAQ","BK4588","BMEA","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2588703853","title":"Biomea Fusion Announces Oral Presentation of Icovamenib at the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588703853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588703853?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:10","pubTimestamp":1764623400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA63KJJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4139","BK4539","BK4585"],"gpt_icon":0},{"id":"2588087777","title":"Biomea Fusion Grants Stock Options to New Employee Under 2023 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588087777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588087777?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623107,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc. has granted a new employee non-qualified stock options to purchase 7,500 shares of the company's common stock. The options will vest at a rate of 1/16 on a quarterly basis over four years, contingent on the employee's continued employment with the company. This award was made under Biomea Fusion's 2023 Inducement Equity Plan, adopted by the board of directors on November 17, 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLcby0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU2210149790.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4539","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BMEA"],"gpt_icon":0},{"id":"2588080257","title":"Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080257","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588080257?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623100,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., Dec.  01, 2025  (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197423/0/en/Biomea-Fusion-Inc-Reports-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4539","BK4585"],"gpt_icon":0},{"id":"2585618724","title":"Biomea Fusion to Join Piper Sandler and Evercore Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585618724","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585618724?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985628,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc., a clinical-stage diabetes and obesity company, will participate in the Piper Sandler 37th Annual Healthcare Conference, with a fireside chat and one-on-one meetings scheduled for December 2, 2025, in New York, NY. The company will also take part in a fireside chat and one-on-one meetings at the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Coral Gables, FL. Audio webcasts of the presentations will be available on Biomea Fusion's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3KQNYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","EVR","BK4127","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4539","BK4585","IE00BGHQF748.EUR","PIPR","BK4112","BMEA","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2584662331","title":"JPMorgan Downgrades Biomea Fusion to Underweight From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2584662331","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584662331?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:35","pubTimestamp":1763382920,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc (BMEA) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMEA"],"gpt_icon":0},{"id":"2584610089","title":"U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior Living","url":"https://stock-news.laohu8.com/highlight/detail?id=2584610089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584610089?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:05","pubTimestamp":1763366750,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Applied Materials, Blackstone Mortgage, Brookdale Senior LivingNov 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL4N3WT0FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BXMT","LU0068578508.USD","PNTG","GB00B4LPDJ14.GBP","XOM","BK4084","GPOR","LU0300736492.USD","PGNY","BK4197","LU2324357040.USD","GAP","BK4566","AMAT","BK4588","TIGO","LU0266512127.USD","LU0251142724.SGD","EXPE","LU2237957902.USD","SR","BK4592","PED","LU0081259029.USD","LU0426417589.USD","BKD","MCK","COR","LU0266013472.USD","LU1228905037.USD","JCAP","MRNA","BLD","PM","FMC","BMEA","PLNT","GRAL","LU0053671581.USD","CDTX","LU0912757837.SGD","COCO","LGN","LU0965509101.SGD","LU2592432038.USD","XYZ","CPB","CGON"],"gpt_icon":1},{"id":"2584217616","title":"Biomea Fusion Inc : JP Morgan Cuts to Underweight From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2584217616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584217616?lang=en_us&edition=fundamental","pubTime":"2025-11-17 12:57","pubTimestamp":1763355453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT09Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4585","BK4539","BK4139"],"gpt_icon":0},{"id":"2583765567","title":"Biomea Fusion downgraded to Underweight from Neutral at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2583765567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583765567?lang=en_us&edition=fundamental","pubTime":"2025-11-15 23:15","pubTimestamp":1763219711,"startTime":"0","endTime":"0","summary":"JPMorgan downgraded Biomea Fusion (BMEA) to Underweight from Neutral without a price target The firm views the recent phase 2 COVALENT II icovameni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-downgraded-to-underweight-from-neutral-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0},{"id":"2582138309","title":"Biomea Fusion Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582138309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582138309?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:54","pubTimestamp":1762811640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 16:54 ET (21:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2582987369","title":"Biomea Fusion Inc. to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582987369","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582987369?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:02","pubTimestamp":1762776145,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc., a clinical-stage diabetes and obesity company, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2025, and in one-on-one meetings on November 17-18, 2025, in London, UK. An audio webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL4WKBJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4539","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","BMEA","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2581773892","title":"Biomea Fusion Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581773892?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:49","pubTimestamp":1762350540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 08:49 ET (13:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":0.1557},{"period":"1month","weight":0.0292},{"period":"3month","weight":-0.2694},{"period":"6month","weight":-0.4025},{"period":"1year","weight":-0.7569},{"period":"ytd","weight":-0.6366}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.103218},{"month":2,"riseRate":0.25,"avgChangeRate":-0.024175},{"month":3,"riseRate":0.25,"avgChangeRate":0.175552},{"month":4,"riseRate":0,"avgChangeRate":-0.168176},{"month":5,"riseRate":0.6,"avgChangeRate":0.133765},{"month":6,"riseRate":0.4,"avgChangeRate":0.081609},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019311},{"month":8,"riseRate":0.8,"avgChangeRate":0.078281},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.126858},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034764},{"month":12,"riseRate":0.4,"avgChangeRate":-0.083462}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction